A Pfizer leader reveals the company's innovation plans around mRNA. Presented by verizonbusiness.
Below is a conversation with Annaliesa Anderson, Pfizer's senior vice president of vaccines research and development. Employees and execs alike at the biotech giant adopted a"light-speed mentality" which focuses on coming up with solutions more quickly and in a more direct manner, without compromising safety.
We also changed our processes. You're no longer setting a strategy and then sitting back and watching that strategy unfold. You're looking at that strategy and reassessing it as you get new data. We asked ourselves"Does something need to be done in the way that we have done it before? Or can we look at things in a different way?"
The flu is another area that we're working on. We've just started our phase-three study of a quadrant flu vaccine made out of mRNA. We see it has several advantages over current flu vaccines, including higher efficacy.Our work on an RSV vaccine for older adults is a great story of partnership and innovation. People have been looking to develop RSV vaccines for over six decades. We've been able to show, in early studies, that our vaccine was highly effective at preventing RSV.
Many companies, including Pfizer, have strategies where we build from within, we partner, and we also make strategic acquisitions. I think that that will remain pretty constant. I think there's a big interest in vaccines now. We're seeing a lot of smaller companies come through and start to really build some momentum in the vaccine space. So there will continue to be interest there. to hire 500 refugees as a response to the recent Afghan and Ukrainian refugee crises.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Pfizer Starts Late-Stage Trial of mRNA-Based Flu VaccinemRNA technology allows changing the influenza vaccine strains relatively faster, and Pfizer expects this flexibility and its rapid manufacturing to potentially allow better strain matches in future years. flushot MedTwitter
Lire la suite »
China's Tianwen 4 to target Jupiter and Uranus with two spacecraft on one rocketChina reveals plans for an ambitious mission that involves a pair of spacecraft targeting Jupiter and Uranus around 2030.
Lire la suite »
Harvard Business Review - The LatestFind new ideas and classic advice on strategy, innovation and leadership, for global leaders from the world's best business and management experts.
Lire la suite »
City Planning Commission approves controversial $2 billion Innovation QNS project in Astoria – QNS.comThe City Planning Commission gave the green light for the massive $2 billion Innovation QNS project in Astoria on Wednesday, Sept. 21.
Lire la suite »
Data & VisualsFind new ideas and classic advice on strategy, innovation and leadership, for global leaders from the world's best business and management experts.
Lire la suite »